190 related articles for article (PubMed ID: 23255183)
1. Facile preparation of mono-, di- and mixed-carboxylato platinum(IV) complexes for versatile anticancer prodrug design.
Zhang JZ; Bonnitcha P; Wexselblatt E; Klein AV; Najajreh Y; Gibson D; Hambley TW
Chemistry; 2013 Jan; 19(5):1672-6. PubMed ID: 23255183
[TBL] [Abstract][Full Text] [Related]
2. Oxidation of 3,6-dioxa-1,8-octanedithiol by platinum(IV) anticancer prodrug and model complex: kinetic and mechanistic studies.
Huo S; Shen S; Liu D; Shi T
J Phys Chem B; 2012 Jun; 116(22):6522-8. PubMed ID: 22574871
[TBL] [Abstract][Full Text] [Related]
3. Dependence of the reduction products of platinum(IV) prodrugs upon the configuration of the substrate, bulk of the carrier ligands, and nature of the reducing agent.
Sinisi M; Intini FP; Natile G
Inorg Chem; 2012 Sep; 51(18):9694-704. PubMed ID: 22921246
[TBL] [Abstract][Full Text] [Related]
4. Influence of equatorial and axial carboxylato ligands on the kinetic inertness of platinum(IV) complexes in the presence of ascorbate and cysteine and within DLD-1 cancer cells.
Chen CK; Zhang JZ; Aitken JB; Hambley TW
J Med Chem; 2013 Nov; 56(21):8757-64. PubMed ID: 24107138
[TBL] [Abstract][Full Text] [Related]
5. Mono- and di-bromo platinum(IV) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity.
Xu Z; Wang Z; Yiu SM; Zhu G
Dalton Trans; 2015 Dec; 44(46):19918-26. PubMed ID: 26514681
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, Structure, and Cytotoxicity of Oxaliplatin-Based Platinum(IV) Anticancer Prodrugs Bearing One Axial Fluoride.
Xu Z; Chan HM; Li C; Wang Z; Tse MK; Tong Z; Zhu G
Inorg Chem; 2018 Jul; 57(14):8227-8235. PubMed ID: 29943979
[TBL] [Abstract][Full Text] [Related]
7. Design and investigation of photoactivatable platinum(iv) prodrug complexes of cisplatin.
Lee VEY; Chin CF; Ang WH
Dalton Trans; 2019 Jun; 48(21):7388-7393. PubMed ID: 30957798
[TBL] [Abstract][Full Text] [Related]
8. What do we know about the reduction of Pt(IV) pro-drugs?
Wexselblatt E; Gibson D
J Inorg Biochem; 2012 Dec; 117():220-9. PubMed ID: 22877926
[TBL] [Abstract][Full Text] [Related]
9. Reactions of a photoactivatable diazido Pt(iv) anticancer complex with a single-stranded oligodeoxynucleotide.
Liang Z; Lin J; Gong X; Cheng Y; Huang C; Zhang J; Wu X; Wang F; Zhao Y; Wu K
Dalton Trans; 2020 Aug; 49(32):11249-11259. PubMed ID: 32756682
[TBL] [Abstract][Full Text] [Related]
10. A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy.
Xiao H; Yan L; Zhang Y; Qi R; Li W; Wang R; Liu S; Huang Y; Li Y; Jing X
Chem Commun (Camb); 2012 Nov; 48(87):10730-2. PubMed ID: 23012698
[TBL] [Abstract][Full Text] [Related]
11.
Lee VEY; Lim ZC; Chew SL; Ang WH
Inorg Chem; 2021 Feb; 60(3):1823-1831. PubMed ID: 33464875
[TBL] [Abstract][Full Text] [Related]
12. Tetracarboxylatoplatinum(IV) complexes featuring monodentate leaving groups - A rational approach toward exploiting the platinum(IV) prodrug strategy.
Höfer D; Varbanov HP; Legin A; Jakupec MA; Roller A; Galanski MS; Keppler BK
J Inorg Biochem; 2015 Dec; 153():259-271. PubMed ID: 26365319
[TBL] [Abstract][Full Text] [Related]
13. Oxidation of anticancer Pt(II) complexes with monodentate phosphane ligands: towards stable but active Pt(IV) prodrugs.
Medrano MÁ; Álvarez-Valdés A; Perles J; Lloret-Fillol J; Muñoz-Galván S; Carnero A; Navarro-Ranninger C; Quiroga AG
Chem Commun (Camb); 2013 May; 49(42):4806-8. PubMed ID: 23591566
[TBL] [Abstract][Full Text] [Related]
14. Importance of platinum(II)-assisted platinum(IV) substitution for the oxidation of guanosine derivatives by platinum(IV) complexes.
Choi S; Vastag L; Larrabee YC; Personick ML; Schaberg KB; Fowler BJ; Sandwick RK; Rawji G
Inorg Chem; 2008 Feb; 47(4):1352-60. PubMed ID: 18220340
[TBL] [Abstract][Full Text] [Related]
15. Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.
Siddik ZH; al-Baker S; Thai G; Khokhar AR
Anticancer Drug Des; 1994 Apr; 9(2):139-51. PubMed ID: 8166929
[TBL] [Abstract][Full Text] [Related]
16. The preparation and characterization of trans-platinum(IV) complexes with unusually high cytotoxicity.
Cubo L; Hambley TW; Sanz Miguel PJ; Carnero A; Navarro-Ranninger C; Quiroga AG
Dalton Trans; 2011 Jan; 40(2):344-7. PubMed ID: 20936210
[TBL] [Abstract][Full Text] [Related]
17. Hydrolysis triggers oxidation of a trans diamine platinum(II) anticancer complex.
Pizarro AM; Munk VP; Navarro-Ranninger C; Sadler PJ
Angew Chem Int Ed Engl; 2003 Nov; 42(43):5339-42. PubMed ID: 14613170
[No Abstract] [Full Text] [Related]
18. Design, synthesis, characterisation and chemical reactivity of mixed-ligand platinum(II) oxadiazoline complexes with potential cytotoxic properties.
Wagner G; Marchant A; Sayer J
Dalton Trans; 2010 Sep; 39(33):7747-59. PubMed ID: 20657943
[TBL] [Abstract][Full Text] [Related]
19. Harnessing chemoselective imine ligation for tethering bioactive molecules to platinum(IV) prodrugs.
Wong DY; Lau JY; Ang WH
Dalton Trans; 2012 May; 41(20):6104-11. PubMed ID: 22426542
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and Characterization of Nitric Oxide-Releasing Platinum(IV) Prodrug and Polymeric Micelle Triggered by Light.
Pramanick S; Kim J; Kim J; Saravanakumar G; Park D; Kim WJ
Bioconjug Chem; 2018 Apr; 29(4):885-897. PubMed ID: 29281788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
